Description:
This project is part of a joint ALFA and GOELAM strategy aiming to improve the survival of
patients with newly diagnosed Acute Myeloid Leukemia (AML) aged 18-70 years. The basis of
this strategy is to evaluate intensified conventional chemotherapy and targeted drugs in
selected disease-risk subgroups of adult patients with non promyelocytic AML. Participation
will be proposed to almost all adult patients in France aged 18-70 years and diagnosed with
AML.
FLT3 genetic alterations include FLT3 somatic point mutations within the second tyrosine
kinase domain and internal duplications of the juxta-membrane domain. This alteration is
refered to as FLT3-ITD. The FLT3-ITD mutation is found in around 30% of patients with
cytogenetically normal AML. Patients with the FLT3-ITD genotype have been reported to have a
poor outcome when treated with conventional chemotherapy with an estimated 4-year
relapse-free survival of 25% (Schlenk et al. N Engl J Med 2008). More recently, the
prognostic relevance of FLT3-ITD has been studied in the context of integrated genetic
profiling. This confirmed the genetic complexity of AML and also that FLT3-ITD was associated
with reduced overall survival in intermediate-risk AML. A multivariate analysis of several
genetic alterations revealed that FLT3-ITD was the primary predictor of patient outcome.
FLT3-ITD mutations were classified in 3 categories: 1) FLT3-ITD with +8, TET2, DNMT3A or
MLL-PTD mutations (3-year OS 14.5%); 2) FLT3-ITD with wild type CEBPA, TET2, DNMT3 and
MLL-PTD (3-year OS 35.2%) and 3) FLT3-ITD with CEBPA mutations (3-year OS 42%) (Patel JP et
al. N Engl J Med 2012). However, FLT3-ITD was not a predictor of response to induction
therapy, allowing the introduction of targeted therapies after the induction course.
Several FLT3 inhibitors have been evaluated or are currently being tested in the setting of
relapsing AML. In most trials to date, patients were only eligible if the FLT3-ITD mutation
was present. Disappointing results were reported with the first generation of FLT3
inhibitors, including lestaurtinib (CEP-701), midostaurin (PKC-412) and sorafenib. Second
generation FLT3 inhibitors such as quizartinib (AC220) are currently under investigation with
promising results. However, the hematologic toxicity of AC220 will likely present a major
limitation in evaluating AC220 combined with standard or high-dose chemotherapy.
Ponatinib (AP24534) is a third generation tyrosine kinase inhibitor targeting the BCR-ABL
tyrosine kinase domain. Ponatinib was rationally designed with an extensive network of
optimized molecular contacts and triple bonds to accommodate the T315I mutation, a major
cause of resistance to tyrosine kinase inhibitors in chronic and advanced phase chronic
myelogenous leukemia (CML). Ponatinib also inhibits SRC (IC50: 5.4 nM) and members of the
VEGFR, FGFR, and PDGFR families of receptor tyrosine kinases (O'Hare T, Cancer Cell 2009).
Despite low activity against FLT3 based on the IC50 value (FLT3 IC50: 12.6 nM compared to BCR
IC50: 0.37 nM), ponatinib has recently been reported to have significant cellular activity
against the MV4-11 cell line which harbors an FLT3-ITD activating mutation. Ponatinib-induced
apoptosis was maximal at 10 nM in vitro and a single dose of 5 and 10 mg/kg had a strong
inhibitory effect in vivo in mice bearing MV4-11 xenografts. Primary blast cells from 4
FLT3-ITD AML patients were also tested and ponatinib reduced their viability (IC50: 4 nM)
whereas no activity was shown on FLT3-ITD-negative blast cells (Gozgit JM et al. Mol Cancer
Ther 2011).
Preliminary data from the phase I clinical trial showed that 15 mg ponatinib was associated
with a Cmax of 51.1 nM. Cmax was increased to 111 nM and 149 nM in the 30 mg and 45 mg
cohorts respectively. The trough concentrations were 55.3 nM and 61.9 nM for the 30 mg and 45
mg doses respectively (Ariad clinical investigator's brochure, version 3). Results from the
ongoing phase II trial in CML patients suggest that the hematological toxicity profile of
ponatinib is comparable with that of nilotinib or dasatinib, both of which have been
successfully combined with conventional chemotherapy.
Investigators thus aim to combine ponatinib with cytarabine in FLT3-ITD AML patients in first
complete remission.
Title
- Brief Title: Ponatinib for FLT3-ITD Acute Myelogenous Leukemia
- Official Title: A Phase I - II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission
Clinical Trial IDs
- ORG STUDY ID:
2013-000268-27
- NCT ID:
NCT02428543
Conditions
Interventions
| Drug | Synonyms | Arms |
|---|
| Ponatinib and Cytarabine | | Ponatinib arm |
Purpose
This project is part of a joint ALFA and GOELAM strategy aiming to improve the survival of
patients with newly diagnosed Acute Myeloid Leukemia (AML) aged 18-70 years. The basis of
this strategy is to evaluate intensified conventional chemotherapy and targeted drugs in
selected disease-risk subgroups of adult patients with non promyelocytic AML. Participation
will be proposed to almost all adult patients in France aged 18-70 years and diagnosed with
AML.
FLT3 genetic alterations include FLT3 somatic point mutations within the second tyrosine
kinase domain and internal duplications of the juxta-membrane domain. This alteration is
refered to as FLT3-ITD. The FLT3-ITD mutation is found in around 30% of patients with
cytogenetically normal AML. Patients with the FLT3-ITD genotype have been reported to have a
poor outcome when treated with conventional chemotherapy with an estimated 4-year
relapse-free survival of 25% (Schlenk et al. N Engl J Med 2008). More recently, the
prognostic relevance of FLT3-ITD has been studied in the context of integrated genetic
profiling. This confirmed the genetic complexity of AML and also that FLT3-ITD was associated
with reduced overall survival in intermediate-risk AML. A multivariate analysis of several
genetic alterations revealed that FLT3-ITD was the primary predictor of patient outcome.
FLT3-ITD mutations were classified in 3 categories: 1) FLT3-ITD with +8, TET2, DNMT3A or
MLL-PTD mutations (3-year OS 14.5%); 2) FLT3-ITD with wild type CEBPA, TET2, DNMT3 and
MLL-PTD (3-year OS 35.2%) and 3) FLT3-ITD with CEBPA mutations (3-year OS 42%) (Patel JP et
al. N Engl J Med 2012). However, FLT3-ITD was not a predictor of response to induction
therapy, allowing the introduction of targeted therapies after the induction course.
Several FLT3 inhibitors have been evaluated or are currently being tested in the setting of
relapsing AML. In most trials to date, patients were only eligible if the FLT3-ITD mutation
was present. Disappointing results were reported with the first generation of FLT3
inhibitors, including lestaurtinib (CEP-701), midostaurin (PKC-412) and sorafenib. Second
generation FLT3 inhibitors such as quizartinib (AC220) are currently under investigation with
promising results. However, the hematologic toxicity of AC220 will likely present a major
limitation in evaluating AC220 combined with standard or high-dose chemotherapy.
Ponatinib (AP24534) is a third generation tyrosine kinase inhibitor targeting the BCR-ABL
tyrosine kinase domain. Ponatinib was rationally designed with an extensive network of
optimized molecular contacts and triple bonds to accommodate the T315I mutation, a major
cause of resistance to tyrosine kinase inhibitors in chronic and advanced phase chronic
myelogenous leukemia (CML). Ponatinib also inhibits SRC (IC50: 5.4 nM) and members of the
VEGFR, FGFR, and PDGFR families of receptor tyrosine kinases (O'Hare T, Cancer Cell 2009).
Despite low activity against FLT3 based on the IC50 value (FLT3 IC50: 12.6 nM compared to BCR
IC50: 0.37 nM), ponatinib has recently been reported to have significant cellular activity
against the MV4-11 cell line which harbors an FLT3-ITD activating mutation. Ponatinib-induced
apoptosis was maximal at 10 nM in vitro and a single dose of 5 and 10 mg/kg had a strong
inhibitory effect in vivo in mice bearing MV4-11 xenografts. Primary blast cells from 4
FLT3-ITD AML patients were also tested and ponatinib reduced their viability (IC50: 4 nM)
whereas no activity was shown on FLT3-ITD-negative blast cells (Gozgit JM et al. Mol Cancer
Ther 2011).
Preliminary data from the phase I clinical trial showed that 15 mg ponatinib was associated
with a Cmax of 51.1 nM. Cmax was increased to 111 nM and 149 nM in the 30 mg and 45 mg
cohorts respectively. The trough concentrations were 55.3 nM and 61.9 nM for the 30 mg and 45
mg doses respectively (Ariad clinical investigator's brochure, version 3). Results from the
ongoing phase II trial in CML patients suggest that the hematological toxicity profile of
ponatinib is comparable with that of nilotinib or dasatinib, both of which have been
successfully combined with conventional chemotherapy.
Investigators thus aim to combine ponatinib with cytarabine in FLT3-ITD AML patients in first
complete remission.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| Ponatinib arm | Experimental | dose-escalation Arm _ 15, 30, 45mg Ponatinib per day. Each cohort will consist of 3 evaluable patients | |
Eligibility Criteria
Inclusion Criteria:
1. a. Patients aged 18 to 55-60 years: Cohort A b. Patients aged 55-60 to 70 years:
Cohort B
2. Signed informed consent
3. Acute myeloid leukemia in first complete remission
4. Platelets ≥ 100 Giga/l; Neutrophils ≥ 1 Giga/l
5. Intermediate risk karyotype with FLT3-ITD activating mutant detected at diagnosis
(mutant FLT3/wild-type allelic ratio higher than 10%) (appendix 16)
6. Induction with intensive chemotherapy, dose dense sequential induction or 3 + 7 like
regimen (daunorubicin or idarubicin) for Cohort A and inclusion in the ALFA backbone
for cohort B.
7. Pancreatic functions within the normal range
8. AST or ALT less or equal to 2.5 fold upper normal range, bilirubin less or equal to
1.5 fold upper normal range
9. Serum creatinine less or equal to 1.5 fold upper normal range
10. Two planned consolidation courses with high-dose cytarabine (HDAC, Cohort A) or
intermediate dose cytarabine (IDAC, Cohort B).
Exclusion Criteria:
1. Acute promyelocytic leukemia
2. Transformation of myeloproliferative or myelodysplastic syndromes
3. Known central nervous system involvement
4. Uncontrolled bacterial, viral or fungal infection
5. Other active malignancy
6. Previous episode of pancreatitis
7. Hypertriglyceridemia > 4.5 g/L
8. Lipase > 1.5 × ULN, amylase > 1.5 x ULN not related to leukemia
9. QTc > 470 ms (Bazett formula, see Appendix 1)
10. Patients at high or very high risk of cardiovascular disease with any of the following
f) Established cardiovascular disease
- Cardiac disease:
- Congestive heart failure greater than class II NYHA or
- Left ventricular ejection fraction (LVEF) < 50% or
- Unstable angina (anginal symptoms at rest) or
- New onset angina (began within the last 3 months) or
- Myocardial infarction, coronary/peripheral artery disease, congestive heart
failure, cerebrovascular accident including transient ischemic attack within
the past 12 months or
- History of thrombolic or embolic events
- Arrhythmias
- Any history of clinically significant cardiac arrhythmias requiring
anti-arrhythmic therapy.
g) Diabetes Mellitus untreated or not equilibrated with therapy h) Arterial
Hypertension,
- - Uncontrolled hypertension defined as systolic blood pressure greater than 140
mmHg or diastolic pressure greater than 90 mmHg, despite optimal medical
management and optimal measurement
(http://www.has-sante.fr/portail/display.jsp?id=c_272459)
- - Any history of hypertension with
- Hypertensive encephalopathy
- Posterior leucoencephalopathy
- Aortic or artery dissection i) Familial dysplipidemia. j) Taking medications
that are known to be associated with Torsades de Pointes (see Appendix 11)
| Maximum Eligible Age: | 70 Years |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | dose-limiting toxicity (DLT) of ponatinib during consolidation 1 with HDAC or IDAC |
| Time Frame: | 12 months |
| Safety Issue: | |
| Description: | assess the safety of increased doses of ponatinib in combination with high or intermediate -dose cytarabine in AML FLT3-ITD patients in first complete remission |
Secondary Outcome Measures
| Measure: | Overall survival |
| Time Frame: | 5 years |
| Safety Issue: | |
| Description: | To determine disease-free survival from achievement of first complete remission |
| Measure: | Relapse-free survival |
| Time Frame: | 5 years |
| Safety Issue: | |
| Description: | To determine overall survival from achievement of first complete remission |
| Measure: | Event-free survival |
| Time Frame: | 5 years |
| Safety Issue: | |
| Description: | To determine overall survival from diagnosis |
| Measure: | Minimal residual disease based on FLT3-ITD quantification, WT1 expression and/or NPM1 mutation quantification |
| Time Frame: | 18 months |
| Safety Issue: | |
| Description: | To study minimal residual disease after induction and consolidation courses based on the quantification of the FLT3-ITD signal and /or WT1, NPM if available |
| Measure: | relationship between minimal residual disease and outcome |
| Time Frame: | 18 months |
| Safety Issue: | |
| Description: | To study the relationship between minimal residual disease and outcome |
| Measure: | To study ponatinib resistance mechanisms |
| Time Frame: | 18 months |
| Safety Issue: | |
| Description: | To assess FLT3-ITD mutant before and after ponatinib treatment |
Details
| Phase: | Phase 1/Phase 2 |
| Primary Purpose: | Interventional |
| Overall Status: | Active, not recruiting |
| Lead Sponsor: | Versailles Hospital |
Trial Keywords
- FLT3-ITD patients in first complete remission
Last Updated
August 10, 2020
